Чему эпидемия COVID-19 научила психиатров?
- Авторы: Менделевич В.Д.1, Гатин Ф.Ф.2, Хамитов Р.Р.1
-
Учреждения:
- Казанский государственный медицинский университет
- Казанская государственная медицинская академия — филиал Российской медицинской академии непрерывного профессионального образования
- Выпуск: Том LIV, № 4 (2022)
- Страницы: 5-13
- Раздел: Передовые статьи
- URL: https://journal-vniispk.ru/1027-4898/article/view/134185
- DOI: https://doi.org/10.17816/nb117637
- ID: 134185
Цитировать
Аннотация
Статья посвящена анализу психопатологических последствий эпидемии COVID-19. Особо подчёркнут факт повышенной летальности от COVID-19 больных шизофренией и аффективными расстройствами. Сделан вывод о том, что на это влияло нерациональное использование антипсихотиков, способствовавших появлению у пациентов сахарного диабета и избыточной массы тела.
Полный текст
Открыть статью на сайте журналаОб авторах
Владимир Давыдович Менделевич
Казанский государственный медицинский университет
Автор, ответственный за переписку.
Email: mendelevich_vl@mail.ru
ORCID iD: 0000-0002-8476-6083
SPIN-код: 2302-2590
Scopus Author ID: 6602765981
докт. мед. наук, проф., зав. каф., каф. психиатрии и медицинской психологии
Россия, КазаньФоат Фаттыхович Гатин
Казанская государственная медицинская академия — филиал Российской медицинской академии непрерывного профессионального образования
Email: bagautdinowa.lejsan@yandex.ru
ORCID iD: 0000-0001-9528-8833
SPIN-код: 1567-9265
Scopus Author ID: 14024231600
докт. мед. наук, проф., зав. каф., каф. психиатрии и судебно-психиатрической экспертизы
Россия, КазаньРустем Радикович Хамитов
Казанский государственный медицинский университет
Email: psycheya.kzn@mail.ru
ORCID iD: 0000-0002-1271-8330
SPIN-код: 4923-9370
докт. мед. наук, проф., каф. психиатрии и медицинской психологии
Россия, КазаньСписок литературы
- Poletti S., Palladini M., Mazza M.G. et al. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: Role of depression and impact on quality of life // European Archives of Psychiatry and Clinical Neuroscience. 2022. Vol. 272. N. 5. P. 773–782. doi: 10.1007/s00406-021-01346-9.
- Raina P., Wolfson Ch., Griffith L. et al. A longitudinal analysis of the impact of the COVID-19 pandemic on the mental health of middle-aged and older adults from the Canadian Longitudinal Study on Aging // Nuture Aging. 2021. Vol. 1. P. 1137–1147. doi: 10.1038/s43587-021-00128-1.
- COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic // Lancet Psychiatry. 2021. Vol. 398. P. 1700–1712. doi: 10.1016/S0140-6736(21)02143-7.
- Мосолов С.Н. Длительные психические нарушения после перенесённой острой коронавирусной инфекции SARS-CoV-2 // Современная терапия психических расстройств. 2021. Т. 3. С. 2–23. doi: 10.21265/PSYPH.2021.31.25.001.
- Менделевич В.Д., Муллина Н.Б. Случай острой гипомании при COVID-19: повинен ли коронавирус? // Психиатрия и психофармакотерапия. 2020. Т. 22. №5. С. 51–54.
- Kozato N., Mishra M., Firdosi M. New-onset psychosis due to COVID-19 // BMJ Case Rep. 2021. Vol. 14. P. e242538. doi: 10.1136/bcr-2021-242538.
- Tariku M., Hajure M. Available evidence and ongoing hypothe-sis on corona virus (COVID-19) and psychosis: Is corona virus and psychosis related? A narrative review // Psychology Research and Behavior Management. 2020. Vol. 13. P. 701–704. doi: 10.2147/PRBM.S264235.
- Parra A., Juanes A., Losada C.P. et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study // Psychiatry Research. 2020. Vol. 291. P. 113254. doi: 10.1016/j.psychres.2020.113254.
- Steardo L.Jr., Steardo L., Verkhratsky A. Psychiatric face of COVID-19 // Translational Psychiatry. 2020. Vol. 10. P. 261. doi: 10.1038/s41398-020-00949-5.
- Rogers J.P., Chesney E., Oliver D. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic // Lancet Psychiatry. 2020. Vol. 7. P. 611–627. doi: 10.1016/S2215-0366(20)30203-0.
- Voitsidis P., Gliatas I., Bairachtari V. et al. Insomnia during the COVID-19 pandemic in a Greek population // Psychiatry Research. 2020. Vol. 289. P. 113076. doi: 10.1016/j.psychres.2020.113076.
- Hartung T.J., Neumann Ch., Bahmer Th. et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study // eClinicalMedicine 2022. Vol. 53. P. 101651. DOI: 10.1016/j. eclinm.2022.101651.
- Houben S., Bonnechère B. The impact of COVID-19 infection on cognitive function and the implication for rehabilitation: A systematic review and meta-analysis // Int. J. Environ. Res. Public Health. 2022. Vol. 19. P. 7748. doi: 10.3390/ijerph19137748.
- Hampshire A., Trender W., Chamberlain S.R. et al. A mehta cognitive deficits in people who have recovered from COVID-19 // eClinicalMedicine. 2021. Vol. 39. Р. 101044. doi: 10.1016/j.eclinm.2021.101044.
- Zhand N., Joober R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: Narrative review // BJPsych Open. 2021. Vol. 7. N. e35. P. 1–7. doi: 10.1192/bjo.2020.157.
- Mohan M., Perry B.I., Saravanan P., Singh S.P. COVID-19 in people with schizophrenia: Potential mechanisms linking schizophrenia to poor prognosis // Front. Psychiatry. 2021. Vol. 12. P. 666067. doi: 10.3389/fpsyt.2021.666067.
- Fonseca L., Diniz E., Mendonca G. et al. Schizophrenia and COVID-19: Risks and recommendations // Braz. J. Psychiatry. 2020. Vol. 42. N. 3. P. 236–238. doi: 10.1590/1516-4446-2020-0010.
- Caqueo-Urizar A., Urzua A., Ponce-Correa F., Ferrer R. Psychosocial effect of the COVID-19 pandemic on patients with schizophrenia and their caregives // Frontiers on Psychology. 2021. Vol. 12 . P. 729793. doi: 10.3389/fpsyg.2021.729793.
- Taquet M., Sillett R., Zhu L. et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1,284,437 patients // Lancet Psychiatry. 2022. Vol. 9. P. 815–827. DOI: 10.1016/ S2215-0366(22)00260-7.
- Bourmistrova N.W., Solomon T., Braude Ph. et al. Long-term effects of COVID-19 on mental health: A systematic review // J. Affect. Disord. 2022. Vol. 299. P. 118–125. doi: 10.1016/j.jad.2021.11.031.
- Brown E.E., Kumar S., Rajji T.K. et al. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias // Am. J. of Geriatric Psychiatry. 2020. Vol. 28. N. 7. P. 712–721. doi: 10.1016/j.jagp.2020.04.010.
- Fond G., Nemani K., Association between mental health disorders and mortality among patients with COVID-19 in 7 countries; A systematic review and meta-analysis // JAMA Psychiatry. 2021. Vol. 78. N. 11. P. 1208–1217. doi: 10.1001/jamapsychiatry.2021.2274.
- Dembosky A. Having schizophrenia is the second biggest risk factor for dying from COVID-19. Connecticut Public. 20 March 2022. https://www.ctpublic.org/2022-03-20/having-schizophrenia-is-the-second-biggest-risk-factor-for-dying-from-covid-19 (access date: 02.12.2022).
- Nemani K., Li Ch., Olfson M. et al. Association of psychiatric disorders with mortality among patients with COVID-19 // JAMA Psychiatry. 2021. Vol. 78. N. 4. P. 380–386. doi: 10.1001/jamapsychiatry.2020.4442.
- Kepinska A.P., Lyegbe C.O., Vermon A.C. et al. Schizophrenia and influenza at the centenary of the 1918–1919 Spanish influenza pandemic: Mechanisms of psychosis risk // Front. Psychiatry. 2020. Vol. 11. P. 72. doi: 10.3389/fpsyt.2020.00072.
- Menninger K.A. Influenza and schizophrenia. An analysis of post-influenzal “dementia precox” as of 1918, and five years later // The American Journal of Psychiatry. 2006. Vol. 82. N. 4. P. 469–529. doi: 10.1176/ajp.82.4.469.
- Brown A.S., Begg M.D., Gravenstein S. et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia // Arch. Gen. Psychiat. 2004. Vol. 61. P. 774–780. doi: 10.1001/archpsyc.61.8.774.
- Pearce B.D. Schizophrenia and viral infection during neurodevelopment: A focus on mechanisms // Mol. Psychiat. 2001. Vol. 6. P. 634–646. doi: 10.1038/sj.mp.4000956.
- Magalhães D., Ferreira F., Ferreira T. et al. Influenza and schizophrenia: How can we shed a light in the new virus from an old association? // European Psychiatry. 2021. Vol. 64. P. 168. doi: 10.1192/j.eurpsy.2021.447.
- Fusick A.J., Gunther S., Sullivan G. The anti-vaccination movement: When does a belief become delusional? // Journal of Public Health. 2021. Vol. 29. P. 1301–1302. doi: 10.1007/s10389-020-01244-9.
- Bitan D.T., Kridin K., Cohen A.D., Weinstein O. COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: A longitudinal cohort study // Lancet Psychiatry. 2021. Vol. 8. P. 901–908. DOI: 10.1016/ S2215-0366(21)00256-X.
- Bitan D.T. Patients with schizophrenia are under-vaccinated for COVID-19: A report from Israel // World Psychiatry. 2020. Vol. 20. N. 2. P. 300–301. doi: 10.1002/wps.20874.
- Nakhaee H., Zangiabadian M., Bayati R. et al. The effect of antidepressants on the severity of COVID-19 in hospitalized patients: Systematic review and meta-analysis // PLoS One. 2022. Vol. 17. N. 10. P. e0267423. doi: 10.1371/journal.pone.0267423.
- Clelland C.L., Ramiah K., Steinberg L., Clelland G.D. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort // BJPsych. Open. 2021. Vol. 8. N. 1. P. e6. doi: 10.1192/bjo.2021.1053.
- Ekinci O. Do we need to change our treatment approach to schizophrenia during the COVID-19 pandemic? // Int. J. Clin. Pract. 2021. Vol. 75. P. e14013. doi: 10.1111/ijcp.14013.
- Pardamean E., Roan W., Amartini Iskandar K.T. et al. Mortality from coronavirus disease 2019 (COVID-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression // Gen. Hosp. Psychiatry. 2022. Vol. 75. P. 61–67. doi: 10.1016/j.genhosppsych.2022.01.010.
- Holt R.I.G. Association between antipsychotic medication use and diabetes // Curr. Diab. Rep. 2019. Vol. 19. N. 10. P. 96. doi: 10.1007/s11892-019-1220-8.
- Azevedo da Silva M., Fournier A., Boutron-Ruault M.C. et al. Increased risk of type 2 diabetes in antidepressant users: Evidence from a 6-year longitudinal study in the E3N cohort // Diabetic Medicine. 2020. Vol. 37. N. 11. P. 1866–1873. doi: 10.1111/DME.14345.
- Wharton S., Raiber L., Serodio K.J. et al. Medications that cause weight gain and alternatives in Canada: A narrative review // Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2018. Vol. 11. P. 427–438. doi: 10.2147/DMSO.S171365.
- Miidera H., Enomoto M., Kitamura S. et al. Association between the use of antidepressants and the risk of type 2 diabetes: A large, population-based cohort study in Japan // Diabetes Care. 2020. Vol. 43. P. 885–893. doi: 10.2337/dc19-1175.
- Gafoor R., Booth H.P., Gulliford M.C. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study // BMJ. 2018. Vol. 23. N. 361. P. k1951. doi: 10.1136/bmj.k1951.
- Reis G., dos Santos Moreira-Silva E.A., Medeiros Silva D.C. et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial // Lancet Glob. Health. 2022. Vol. 10. P. e42–51. DOI: 10.1016/ S2214-109X(21)00448-4.
Дополнительные файлы
